Early cancer detection unicorn Grail files IPO plans

Cancer testing startup Grail Inc. filed plans Wednesday to go public later this year in an offering that reportedly could raise $500 million. The amount quoted in the Menlo Park-based company's Securities and Exchange Commission filing is $100 million, but that is likely a placekeeper figure. Renaissance Capital, which manages exchange-traded funds of IPO stocks, projects Grail will actually raise about half a billion dollars in the IPO. Grail, founded by gene sequencing company Illumina Inc. (NASDAQ:…

Click to view original post